Bio-Rad Laboratories Statistics
Share Statistics
Bio-Rad Laboratories has 27.27M
shares outstanding. The number of shares has increased by -1.66%
in one year.
| Shares Outstanding | 27.27M |
| Shares Change (YoY) | -1.66% |
| Shares Change (QoQ) | 0.31% |
| Owned by Institutions (%) | 71.02% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 44 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.32M, so 4.7% of the outstanding
shares have been sold short.
| Short Interest | 1.32M |
| Short % of Shares Out | 4.7% |
| Short % of Float | 7.59% |
| Short Ratio (days to cover) | 3.51 |
Valuation Ratios
The PE ratio is -5.03 and the forward
PE ratio is 23.14.
Bio-Rad Laboratories's PEG ratio is
-0.03.
| PE Ratio | -5.03 |
| Forward PE | 23.14 |
| PS Ratio | 3.61 |
| Forward PS | 2.1 |
| PB Ratio | 1.41 |
| P/FCF Ratio | 34.82 |
| PEG Ratio | -0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Bio-Rad Laboratories.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.48,
with a Debt / Equity ratio of 0.21.
| Current Ratio | 6.48 |
| Quick Ratio | 6.48 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | -0.65 |
| Debt / FCF | 5.16 |
| Interest Coverage | 5.5 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $333,311.69 |
| Profits Per Employee | $-239,506.49 |
| Employee Count | 7,700 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -498.3M |
| Effective Tax Rate | 21.27% |
Stock Price Statistics
The stock price has increased by -19.39% in the
last 52 weeks. The beta is 1, so Bio-Rad Laboratories's
price volatility has been higher than the market average.
| Beta | 1 |
| 52-Week Price Change | -19.39% |
| 50-Day Moving Average | 241.21 |
| 200-Day Moving Average | 305.05 |
| Relative Strength Index (RSI) | 42.21 |
| Average Volume (20 Days) | 372,281 |
Income Statement
In the last 12 months, Bio-Rad Laboratories had revenue of 2.57B
and earned -1.84B
in profits. Earnings per share was -65.36.
| Revenue | 2.57B |
| Gross Profit | 1.38B |
| Operating Income | 269M |
| Net Income | -1.84B |
| EBITDA | -2.1B |
| EBIT | -2.29B |
| Earnings Per Share (EPS) | -65.36 |
Full Income StatementBalance Sheet
The company has 488.1M in cash and 1.37B in
debt, giving a net cash position of -886.6M.
| Cash & Cash Equivalents | 488.1M |
| Total Debt | 1.37B |
| Net Cash | -886.6M |
| Retained Earnings | 7.42B |
| Total Assets | 9.53B |
| Working Capital | -503.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 455.2M
and capital expenditures -189M, giving a free cash flow of 266.2M.
| Operating Cash Flow | 455.2M |
| Capital Expenditures | -189M |
| Free Cash Flow | 266.2M |
| FCF Per Share | 9.44 |
Full Cash Flow StatementMargins
Gross margin is 53.73%, with operating and profit margins of 10.48% and -71.86%.
| Gross Margin | 53.73% |
| Operating Margin | 10.48% |
| Pretax Margin | -91.27% |
| Profit Margin | -71.86% |
| EBITDA Margin | -81.85% |
| EBIT Margin | 10.48% |
| FCF Margin | 10.37% |
